Lymphoma is not a single disease. It’s an umbrella term for cancers that start in the lymphatic system, the network of vessels and nodes that helps your body fight infection. The two main types are Hodgkin lymphoma and non-Hodgkin lymphoma (NHL). So non-Hodgkin lymphoma isn’t something separate from lymphoma; it’s one of the two major categories within it.
The distinction matters because these two types behave differently, show up at different ages, and require different treatment approaches. Understanding which category a lymphoma falls into is the first step in figuring out how aggressive it is and how to treat it.
How Hodgkin and Non-Hodgkin Lymphoma Differ
The defining difference comes down to what pathologists see under a microscope. Hodgkin lymphoma contains distinctive abnormal cells called Reed-Sternberg cells, which are large and often described as looking like owl’s eyes. When a biopsy sample shows these cells, the diagnosis is Hodgkin lymphoma. When they’re absent, it’s classified as non-Hodgkin lymphoma.
Beyond that cellular hallmark, the tissue itself looks different. Hodgkin lymphoma biopsy samples are filled with inflammation surrounding the cancer cells. Non-Hodgkin lymphoma samples typically lack that inflammatory background. Pathologists also use specific protein markers on the cell surface to confirm the diagnosis. In classic Hodgkin lymphoma, the Reed-Sternberg cells strongly express a marker called CD30, while most non-Hodgkin lymphomas test positive for different markers depending on whether they arise from B cells or T cells.
Non-Hodgkin Lymphoma Is Far More Common
Non-Hodgkin lymphoma accounts for the vast majority of lymphoma diagnoses. An estimated 80,350 new cases of NHL will be diagnosed in the United States in 2025, with a rate of about 18.7 new cases per 100,000 people per year. Hodgkin lymphoma, by comparison, makes up roughly 10% of all lymphoma cases.
The age patterns differ too. Hodgkin lymphoma has a bimodal age distribution, peaking in young adults (typically ages 15 to 35) and again in adults over 55. Non-Hodgkin lymphoma, on the other hand, becomes steadily more common with age and is most frequently diagnosed in people over 60.
Non-Hodgkin Lymphoma Has Dozens of Subtypes
One reason non-Hodgkin lymphoma can be confusing is that it’s not really one disease either. It’s a collection of more than 60 different subtypes, each with its own behavior, prognosis, and treatment strategy. These subtypes are grouped by the type of immune cell they originate from.
Most non-Hodgkin lymphomas (about 85%) arise from B cells, the immune cells that produce antibodies. The most common B-cell subtypes include diffuse large B-cell lymphoma (the most frequently diagnosed aggressive form), follicular lymphoma (a slower-growing type), mantle cell lymphoma, marginal zone lymphoma, and Burkitt lymphoma. The remaining cases come from T cells or natural killer cells. Adult T-cell lymphoma and mycosis fungoides (a lymphoma that primarily affects the skin) are the most common T-cell varieties.
Geography plays a role in which subtypes are most prevalent. Follicular lymphoma is more common in Western countries, while T-cell lymphomas are diagnosed more frequently in Asia. This variation likely reflects differences in genetic susceptibility and environmental exposures.
How Each Type Spreads
Hodgkin lymphoma tends to spread in an orderly, predictable fashion, moving from one group of lymph nodes to the next in sequence. This predictability is one reason it responds well to treatment: doctors can often anticipate where the disease will go next and target those areas.
Non-Hodgkin lymphoma is less predictable. It can arise in lymph nodes throughout the body and may skip to distant node groups or spread to organs outside the lymphatic system, such as the stomach, skin, or brain. Research shows that different NHL subtypes have preferential sites where they tend to appear first, suggesting that local factors like chronic infection or persistent immune stimulation at specific locations may contribute to where these cancers develop.
Treatment and Outlook
Hodgkin lymphoma is one of the most curable cancers. Even in advanced stages, the majority of patients achieve long-term remission with chemotherapy, radiation, or a combination. The predictable spread pattern and the responsiveness of Reed-Sternberg cells to treatment contribute to these high cure rates.
Non-Hodgkin lymphoma is harder to generalize about because the outlook varies enormously by subtype. Aggressive forms like diffuse large B-cell lymphoma grow quickly but often respond well to intensive chemotherapy, with many patients achieving a cure. Slower-growing (indolent) forms like follicular lymphoma may not need immediate treatment at all. Some patients live for years with indolent NHL under a “watch and wait” approach, only starting treatment when symptoms develop or the disease progresses.
The treatment toolkit for NHL has expanded significantly in recent years. In addition to traditional chemotherapy and radiation, options now include targeted therapies that home in on specific proteins on the surface of lymphoma cells, immunotherapies that help the immune system recognize and attack the cancer, and in some cases, CAR-T cell therapy, where a patient’s own immune cells are engineered to fight the lymphoma.
Why the Distinction Matters for You
If you or someone you know has been told they have lymphoma, the single most important piece of information is the specific subtype. “Lymphoma” alone tells you very little about what to expect. Hodgkin lymphoma and non-Hodgkin lymphoma are staged and treated differently, and within non-Hodgkin lymphoma, the difference between subtypes can be as significant as the difference between entirely separate cancers. A diagnosis of indolent follicular lymphoma, for example, carries a very different prognosis and treatment timeline than aggressive Burkitt lymphoma, even though both fall under the NHL umbrella.
The subtype is determined through biopsy, where tissue is examined under a microscope and tested for specific protein markers on the cell surface. B-cell lymphomas express one set of markers, T-cell lymphomas another, and Hodgkin lymphoma has its own distinctive pattern centered on CD30. These molecular details guide every treatment decision that follows.